Antiangiogenic therapy in cancer: a new era has begun.
Grothey
Axel
A
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016503:Drug Delivery Systems / Q000639:trends; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab